Analysts Expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) Will Announce Earnings of -$0.29 Per Share


Share on StockTwits

Analysts expect CytomX Therapeutics, Inc. (NASDAQ:CTMX) to post earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for CytomX Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.06) and the lowest estimate coming in at ($0.51). CytomX Therapeutics reported earnings per share of $0.26 in the same quarter last year, which indicates a negative year-over-year growth rate of 211.5%. The business is expected to report its next earnings report on Thursday, May 6th.

According to Zacks, analysts expect that CytomX Therapeutics will report full-year earnings of ($1.24) per share for the current fiscal year, with EPS estimates ranging from ($2.00) to ($0.29). For the next fiscal year, analysts expect that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.18) to ($0.84). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow CytomX Therapeutics.

CytomX Therapeutics (NASDAQ:CTMX) last released its earnings results on Tuesday, February 23rd. The biotechnology company reported ($0.32) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.18. The firm had revenue of $16.37 million during the quarter, compared to analyst estimates of $17.86 million. CytomX Therapeutics had a negative return on equity of 94.20% and a negative net margin of 58.13%.

Several research analysts have recently commented on CTMX shares. JPMorgan Chase & Co. began coverage on CytomX Therapeutics in a research report on Monday, March 29th. They issued an “overweight” rating and a $14.00 target price for the company. Zacks Investment Research upgraded CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a research report on Tuesday, March 9th. Finally, Jefferies Financial Group upgraded shares of CytomX Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, March 29th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $11.63.

CTMX traded up $0.10 during trading hours on Monday, reaching $7.61. 23,772 shares of the stock traded hands, compared to its average volume of 1,002,535. The firm’s fifty day simple moving average is $7.96 and its two-hundred day simple moving average is $7.51. The company has a market cap of $493.01 million, a price-to-earnings ratio of -6.39 and a beta of 0.74. CytomX Therapeutics has a fifty-two week low of $6.25 and a fifty-two week high of $15.44.

In other CytomX Therapeutics news, CEO Sean A. Mccarthy sold 100,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 31st. The shares were sold at an average price of $7.49, for a total transaction of $749,000.00. Following the sale, the chief executive officer now directly owns 306,894 shares in the company, valued at approximately $2,298,636.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 5.80% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Federated Hermes Inc. grew its stake in shares of CytomX Therapeutics by 1,863.3% in the fourth quarter. Federated Hermes Inc. now owns 362,658 shares of the biotechnology company’s stock worth $2,375,000 after purchasing an additional 344,186 shares during the last quarter. Sei Investments Co. bought a new stake in CytomX Therapeutics during the 3rd quarter valued at $717,000. Barclays PLC increased its position in shares of CytomX Therapeutics by 204.7% during the fourth quarter. Barclays PLC now owns 90,014 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 60,474 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of CytomX Therapeutics by 26.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 218,763 shares of the biotechnology company’s stock valued at $1,433,000 after acquiring an additional 45,887 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its stake in CytomX Therapeutics by 98.3% during the fourth quarter. Squarepoint Ops LLC now owns 76,808 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 38,065 shares during the period. 77.87% of the stock is currently owned by institutional investors and hedge funds.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors.

Featured Story: Insider Trading

Get a free copy of the Zacks research report on CytomX Therapeutics (CTMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.